Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
This activity is supported by an educational grant from AstraZeneca.
September 2024
CD19-CAR T-cell therapy induces deep tissue depletion of B cells
Ann Rheum Dis 2024;0:1–8 DOI 10.1136/ard-2024-226142
Tur et al. demonstrated that CD19-targeting CAR T-cell therapy results in the depletion of B cells within deep tissues. The study highlights significant reductions in pathogenic B-cell populations, particularly in autoimmune diseases, after CD19-CAR T-cell administration.
Keywords:
November 2022
Anti-CD19 CAR T Cell Therapy for Refractory Systemic Lupus Erythematosus
Nat Med. 2022;28(10):2124–2132 doi: 10.1038/s41591-022-02017-5
Data suggest that CD19 chimeric antigen receptor (CAR) T cell transfer is feasible, tolerable and highly effective in patients with SLE.
Keywords:
May 2022
Efficacy and Safety of Obinutuzumab in Systemic Lupus Erythematosus Patients with Secondary Non-response to Rituximab
Rheumatology 2022;00:1–5 DOI.org/10.1093/rheumatology/keac150
Arnold, et al. present the first case series reporting the efficacy and safety of obinutuzumab in patients with treatment refractory SLE. The results indicate that, for this group of patients with limited treatment approaches, obinutuzumab could be a potential option.
Keywords:
November 2021
B-cell Depletion With Obinutuzumab for the Treatment of Proliferative Lupus Nephritis: A Randomised, Double-blind, Placebo-controlled Trial
Ann Rheum Dis. 2021. doi:10.1136/annrheumdis-2021-220920
Phase 2 study data support the use of obinutuzumab in proliferative lupus nephritis (LN) being further evaluated in a global Phase 3 study.